Prozac - Controversial Blockbuster: Case Histories of Transformational Advances

Posted: 16 Jun 2021 Last revised: 28 Dec 2024

See all articles by Amar Bhide

Amar Bhide

Columbia University - Mailman School of Public Health

Srikant Datar

Harvard University - Accounting & Control Unit

Katherine Stebbins

Harvard University - Business School (HBS)

Date Written: May 31, 2024

Abstract

This case history describes the development of Prozac, a blockbuster drug that transformed the treatment of depression – and became a cultural phenomenon in the United States. Specifically, we chronicle the: 1) prior treatments for depression and the research that provided a foundation for Prozac, before 1970; 2) development of Prozac, from 1971 to 1987; and 3) rapid adoption in the US after 1988.

Keywords: Health Care and Treatment, Technological Innovation, Innovation, Technology Adoption, Invention; Governing Rules, Regulations, and Reforms

Suggested Citation

Bhide, Amar and Datar, Srikant and Stebbins, Katherine, Prozac - Controversial Blockbuster: Case Histories of Transformational Advances (May 31, 2024). Harvard Business School General Management Unit Working Paper No. 20-135, Harvard Business School Accounting & Management Unit Working Paper No. 20-135, Available at SSRN: https://ssrn.com/abstract=3866769 or http://dx.doi.org/10.2139/ssrn.3866769

Amar Bhide (Contact Author)

Columbia University - Mailman School of Public Health ( email )

600 West 168th St., 6th Floor
New York, NY 10032
United States

Srikant Datar

Harvard University - Accounting & Control Unit ( email )

Soldiers Field
Boston, MA 02163
United States
617-495-6543 (Phone)
617-496-7363 (Fax)

Katherine Stebbins

Harvard University - Business School (HBS) ( email )

Soldiers Field Road
Morgan 270C
Boston, MA 02163
United States

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
116
Abstract Views
1,034
Rank
483,871
PlumX Metrics